We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.51B
AUM Growth
-$65.2M
Cap. Flow
+$241M
Cap. Flow %
16.02%
Top 10 Hldgs %
78.74%
Holding
39
New
5
Increased
3
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
ADAP
Adaptimmune Therapeutics
ADAP
+$80.8M
2
SENS icon
Senseonics Holdings Inc
SENS
+$74M
3
TSRO
TESARO, Inc.
TSRO
+$57M
4
KA
Kineta, Inc. Common Stock
KA
+$24.4M
5
ELGX
Endologix Inc
ELGX
+$20.5M

Top Sells

Rank Stock Value
1
TRIV
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
+$26.2M
2
NVRO
NEVRO CORP.
NVRO
+$19.6M
3
AKTX
Akari Therapeutics
AKTX
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 74.03%
2 Communication Services 11.7%
3 Technology 6.13%
4 Consumer Discretionary 1.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$452M 30.04%
10,275,113
+1,420,858
+16% +$57M
GRPN icon
2
Groupon
GRPN
$1.05B
$176M 11.7%
2,208,648
– –
ARDX icon
3
Ardelyx
ARDX
$1.24B
$91.6M 6.08%
11,792,631
+1,498,535
+15% +$14.8M
ADAP
4
DELISTED
Adaptimmune Therapeutics
ADAP
$80.3M 5.33%
+9,880,999
New +$80.8M
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$75.9M 5.04%
6,260,851
+1,111,111
+22% +$11.2M
SENS icon
6
Senseonics Holdings Inc
SENS
$255M
$75.2M 5%
+1,315,159
New +$74M
DERM
7
DELISTED
Dermira, Inc.
DERM
$72.5M 4.82%
3,506,649
– –
OPWR
8
DELISTED
OPOWER INC COM STK (DE)
OPWR
$61.3M 4.07%
8,997,290
– –
CBIO
9
Crescent Biopharma
CBIO
$598M
$51.2M 3.4%
85,841
– –
LOXO
10
DELISTED
Loxo Oncology, Inc
LOXO
$49M 3.25%
1,792,207
– –
NVRO
11
DELISTED
NEVRO CORP.
NVRO
$37.2M 2.47%
660,428
-333,000
-34% -$19.6M
TRVN
12
DELISTED
Trevena, Inc.
TRVN
$31.5M 2.09%
6,099
– –
KA
13
DELISTED
Kineta, Inc. Common Stock
KA
$29.8M 1.98%
+22,109
New +$24.4M
LXRX icon
14
Lexicon Pharmaceuticals
LXRX
$1.03B
$28.5M 1.89%
2,382,286
– –
HIVE
15
DELISTED
Aerohive Networks
HIVE
$23.4M 1.55%
4,681,455
– –
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
$21.9M 1.45%
1,139,890
– –
ELGX
17
DELISTED
Endologix Inc
ELGX
$20.8M 1.38%
+249,020
New +$20.5M
CRCM
18
DELISTED
CARE.COM, INC.
CRCM
$20.1M 1.33%
3,260,989
– –
TCON
19
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$13.2M 0.88%
9,448
– –
SYBX
20
DELISTED
Synlogic
SYBX
$13M 0.86%
28,332
– –
SBBP
21
DELISTED
Strongbridge Biopharma plc.
SBBP
$9.76M 0.65%
2,141,308
– –
EXEL icon
22
Exelixis
EXEL
$14B
$8.83M 0.59%
2,207,000
– –
DZSI
23
DELISTED
DZS Inc. Common Stock
DZSI
$7.65M 0.51%
956,258
– –
AUPH icon
24
Aurinia Pharmaceuticals
AUPH
$1.92B
$7.41M 0.49%
2,546,843
– –
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$709M
$6.75M 0.45%
324,315
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q1 2016 Portfolio in Review

As of Q1 2016, NEA Management Company held 39 positions worth $1.51B, down 4.1% from $1.57B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

NEA Management Company deployed $241M of net new capital in Q1 2016, opening 5 new positions and adding to 3 existing holdings. Its largest new stake was Adaptimmune Therapeutics: 9,880,999 shares worth $80.3M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 72% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was NEVRO CORP., an estimated $19.6M trimmed.

  • NEA Management Company's largest Q1 2016 buy was Adaptimmune Therapeutics: 9,880,999 shares worth $80.3M.
  • NEA Management Company added most to TESARO, Inc. in Q1 2016, an estimated $57M increase.
  • NEA Management Company's biggest Q1 2016 reduction was NEVRO CORP., cutting an estimated $19.6M.
  • NEA Management Company fully exited TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK in Q1 2016, selling an estimated $26.2M.
  • NEA Management Company's ten largest holdings make up 79% of its $1.51B portfolio in Q1 2016.
  • NEA Management Company opened 5 new positions and closed 2 in Q1 2016.
  • NEA Management Company's portfolio value fell 4.1% quarter-over-quarter to $1.51B.

Based on NEA Management Company's 13F filing for Q1 2016, filed 11 May 2016.